Skip to content
Checked.be
Complete company report
Generated 13-08-2026
Active BE 0776.937.633Limited partnership

Groovy.Bio

Uitbreidingstraat 66 ·2600 Antwerpen, Belgium· 4 yrs active
Sector: Vervaardiging van geneesmiddelen (21201)
Conclusion Checked

The computed 12-month bankruptcy probability of Groovy.Bio is 0.5% (very low). The 2025 annual accounts show equity of €544k and a net result of €-298k. Equity is growing by ~74.4% per year across the filed fiscal years. The company has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals.

Based on the State Gazette, CBE and 4 annual accounts.
Key figures
Equity €544k
Net result €-298k
Staff (FTE) 0.2
Active 4 yrs
Snowflake analysis 5 of 5 axes measured · computed by Checked
Health63Profitability0Solvency100Growth52Stability94
62 / 100

Strong profile, led by solvency.

All 5 axes are computed from data Checked has read.

Health 63
Profitability 0
Solvency 100
Growth 52
Stability 94
Bankruptcy probability (12 mo) Checked model v1 · free
0.5% Very low
0%0,5%1,5%4%10%≥25%
Lower-risk legal form −Young company +Higher-failure-rate sector +

Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?

Risk Assessment rule-based
0 / 100
Low risk
Trust signals 2 signals
More than 3 years active
Founded in 2021, past the statistically most fragile first 3 years.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags 0 events
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Health barometer FY 2025 · computed
63 / 100 Healthy
050100
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.

Unlock the full score breakdown, per-year score history and the indicative credit limit from Kantoor S.

See plans →
Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.
Financial overview4 NBB filings
Annual accounts filed on 12-05-2026 with the NBB · fiscal year 2025 · verkort
€-400k€-300k€-200k€-100k€0Operating result 2022: €-11k€-11kNet result 2022: €-11k€-11kOperating result 2023: €-11k€-11kNet result 2023: €-19k€-19kOperating result 2024: €-384k€-384kNet result 2024: €-344k€-344kOperating result 2025: €-306k€-306kNet result 2025: €-298k€-298k2022202320242025
Operating resultNet result
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
growing Equity: growth of ~74.4%/year over 4 fiscal years, indicative, assuming unchanged policy.
€0€1.00M€2.00M€3.00M2026: €972k (€928k - €1.02M)2027: €1.69M (€1.65M - €1.74M)2028: €2.95M (€2.90M - €3.01M)2022: €89k2023: €671k2024: €327k2025: €544k2022202320242025202620272028
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?

The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.

The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.

A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).

EBITDA
€-30k
+50.5% 22-25
Net profit
€-298k
+13.4% 22-25
Cash flow
€-21k
-3.9% 22-25
Total assets
€744k
+104.9% 22-25
Equity
€544k
+66.5% 22-25
Working capital
€636k
+94.5% 22-25
Employees (FTE)
0
- 22-25
Staff costs
€12k
- 22-25
Income taxes
€-9k
+25.5% 22-25
Debt
€200k
+453.1% 22-25
Debt ≤ 1y
€108k
+199.2% 22-25
Current ratio
6.89
-31.5% 22-25
Quick ratio
6.89
-31.5% 22-25
Solvency
73.2%
-18.7% 22-25
Debt / equity
0.37
+232.2% 22-25
ROE
-54.6%
+48.0% 22-25
ROA
-40.0%
+57.7% 22-25
Interest coverage
-64.06
+53.2% 22-25
Figures by fiscal year
Fiscal year2025
Depositverkort
Revenue-
EBITDA€-30k
Net profit€-298k
Cash flow€-21k
Staff costs€12k
Income taxes€-9k
Dividends-
Total assets€744k
Equity€544k
Debt€200k
of which ≤ 1y€108k
of which > 1y-
Working capital€636k
Employees (FTE)0.2
Ratios (computed)
2025
Current ratio6.89
Quick ratio6.89
Working capital ratio85.5%
Solvency73.2%
Debt / equity0.37
Long-term debt ratio-
Interest coverage-64.06
Gross margin-
Net margin-
ROA-40.0%
ROE-54.6%
EBITDA margin-
Days sales outstanding-
Days payable outstanding-
Inventory turnover-
Days inventory (DSI)-
Balance-sheet composition 2025
Full annual accounts
Filed balance sheet and income statement, exactly as deposited with the NBB.
Line item Code2025
Balance sheet, Assets
TOTAL ASSETS 20/58€744k
Fixed assets 21/28€1
Financial fixed assets 28€1
Current assets 29/58€744k
Amounts receivable within one year 40/41€16k
Cash & bank 54/58€694k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES 10/49€744k
Equity 10/15€544k
Contributions / capital 10/11€842k
Accumulated profits (losses) 14€-298k
Amounts payable 17/49€200k
Amounts payable within one year 42/48€108k
Trade debts payable within one year 44€106k
Income statement
Gross operating margin 9900€-18k
Operating result 9901€-306k
Financial income 75€0
Financial charges 65€465
Result before taxes 9903€-307k
Income taxes 67/77€-9k
Net result for the period 9904€-298k
Result to be appropriated 9905€-298k
You're seeing the latest fiscal year only. Unlock 3 prior years (figures + ratios) with a paid plan. See plans →
Ratios computed by Checked.
Legal Structure
NACE primary Vervaardiging van geneesmiddelen(21201)
Legal form Limited partnership(612)
Incorporation08-11-2021
StatusActive
Postal code2600
Connections & network 22 connected companies
Network connections
Auroras
Shared address
→
FINARMIT
Shared address
→
FINEG
Shared address
→
FINMALT
Shared address
→
INTERVEST
Shared address
→
Intervest 2 Puurs
Shared address
→
INTERVEST BERINGEN
Shared address
→
INTERVEST CHARLEROI
Shared address
→
INTERVEST GEMBLOUX
Shared address
→
INTERVEST TESSENDERLO
Shared address
→
Kumo Bouwwerken
Shared address
→
→
Recub
Shared address
→
STRIJDER
Shared address
→
THE PARKING LOT
Shared address
→
Vastned
Shared address
→
→
WOW BELGIUM
Shared address
→
→
Connections derived from shared directors, addresses, shareholders and group structure in the Belgian State Gazette.
Establishment units 1 location
Bioqube Factory Project Company
Uitbreidingstraat 66, 2600 AntwerpenOnderzoek en op punt stellen van de productie van actief geneeskrachtige substanties, bestemd voor de vervaardiging van geneesmiddelen
since 20212.325.629.042
Physical sites registered in the Crossroads Bank for Enterprises (CBE).
Real-estate footprint Source: CBE × cadastre

Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.

Flanders 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
11303B0445/00F008 Flanders 2,372 m² 1 · 792 m² 23.9 m · 7 fl.
Methodology
via registered seat: 1
1 of 1 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Updates 6 events

A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.

2026
12-05-2026
NBB filing Annual accounts filed
fiscal year 2025 · verkort
2025
16-12-2025
State Gazette act Capital & shares
v3.2
09-07-2025
State Gazette act Registered-office change
v3.2
11-04-2025
NBB filing Annual accounts filed
fiscal year 2024 · verkort
2024
03-04-2024
NBB filing Annual accounts filed
fiscal year 2023 · verkort
2023
28-06-2023
NBB filing Annual accounts filed
fiscal year 2022 · verkort
Belgisch Staatsblad, acts 2 acts
Capital history · 1
16-12-2025
v3.2
Address history · 1
09-07-2025
v3.2
All acts · 2 updated 8 months ago
2025
16-12-2025 Capital increase of €515,000 Capital & shares
Summary: v3.2
Technical details 
{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 515000,
      "currency": "EUR",
      "after_eur": null,
      "delta_eur": 515000,
      "before_eur": null,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2025-10-28",
      "evidence_quote": "Bioqube brengt een bedrag in van 515 000 euro (vijfhonderdvijftien duizend euro) in ruil voor 515 000 aandelen. Deze inbreng in geld wordt uiterlijk op 7 november 2025 volstort op de bankrekening van Groovy.Bio bij Belfius bank.",
      "contribution_type": "cash"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0776.937.633",
    "name_full": "GROOVY.BII",
    "legal_form": "CommV"
  }
}
09-07-2025 Registered office moved from Beerse to Berchem Registered-office change
  • Turnhoutseweg 30, 2340 Beerse → Uitbreidingstraat 66, 2600 Berchem
Summary: v3.2
Technical details 
{
  "events": [
    {
      "kind": "zetel_transfer",
      "seat_type": "statutaire",
      "new_address": {
        "city": "Berchem",
        "region": "Vlaams Gewest",
        "street": "Uitbreidingstraat",
        "country": "BE",
        "postcode": "2600",
        "box_number": "31",
        "street_number": "66"
      },
      "old_address": {
        "city": "Beerse",
        "region": "Vlaams Gewest",
        "street": "Turnhoutseweg",
        "country": "BE",
        "postcode": "2340",
        "box_number": null,
        "street_number": "30"
      },
      "effective_date": "2025-03-21",
      "evidence_quote": "De vergadering beslist, bij afzonderlijke stemming, om met onmiddellijke ingang, de maatschappelijke zetel te verplaatsen naar Uitbreidingstraat 66 bus 31, 2600 Berchem."
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0776.937.633",
    "name_full": "BIOQUBE FACTORY PROJECT COMPANY",
    "legal_form": "CommV"
  }
}
Credit advice verdict per customer and amount

Should this customer buy amount X on invoice? Enter the amount and payment terms, you get an instant GREEN/AMBER/RED verdict, with a suggested ceiling and concrete conditions.

Based on official sources (NBB, CBE, State Gazette). Indicative, not credit advice.
AI due-diligence brief Checked AI

Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.

Coming soon
The brief is drafted by our AI model at Anthropic in the US, from this dossier's public data. Nothing that identifies you is sent along and we do not keep the brief. Indicative, not legal or investment advice. How it works
Company registry (CBE) Crossroads Bank
Activities
Vervaardiging van geneesmiddelen21201Vervaardiging van geneesmiddelen21201Speur- en ontwikkelingswerk op biotechnologisch gebied72101Vervaardiging van overige farmaceutische producten21209Vervaardiging van overige farmaceutische producten21209Overige ondersteunende activiteiten in verband met financiële diensten, exclusief verzekeringen en pensioenfondsen, n.e.g.66199Overige ondersteunende activiteiten in verband met financiële diensten, neg, exclusief verzekeringen en pensioenfondsen66199Speur- en ontwikkelingswerk op biotechnologisch gebied72101Speur- en ontwikkelingswerk op biotechnologisch gebied72110Overige gespecialiseerde wetenschappelijke en technische activiteiten74909Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg74999
Primary activity highlighted.
Names & trade names
Legal nameNL Groovy.Bio
AbbreviationNL BFPC
Registered office
Uitbreidingstraat 66 bus 31
2600 Antwerpen, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.
Similar companies Comparable size · 26 of 148 companies in this sector with filed accounts
OLYS Pharma BE 0754.895.372 · La Hulpe
272BIO BE 0762.638.249 · Gent
MITHRA PHARMACEUTICALS CDMO BE 0534.912.933 · Liège
ASTEL MEDICA BE 0472.890.044 · Tinlot
White Raven BE 0782.537.107 · Liège
Source: Belgian State Gazette, CBE, NBB · generated via checked.be · indicative